International Journal of Medical Imaging

| Peer-Reviewed |

Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer

Received: 31 October 2015    Accepted: 10 November 2015    Published: 26 November 2015
Views:       Downloads:

Share This Article

Abstract

Prostate cancer (PCa) represents the most common non-cutaneous malignancy for men, where an estimated 241,740 new cases will be diagnosed in 2013 in the United States [1]. Whereas most of those new diagnoses will be clinically localized, up to 17% of patients may experience metastatic disease, in which the risk of cancer- specific mortality is increased [2]. In this context, it is well established that, beyond regional lymph nodes, the skeleton represents the most common metastatic site [3].The study aims to evaluate the pattern of distribution of bone metastases in prostate cancer patients by 99mTc- methylene diphosphonate (99mTc-MDP) bone scintigraphy. It was formed in 150 patients with pathologically proven prostate cancer and presented for bone scans with 99mTc-methylene diphosphonate (99mTc-MDP) for detection and evaluation of bone metastases. It was noted that patients with bone metastases had significantly higher frequency of bone pain when compared with patients without and noted that spine was the most commonly affected site (60.0 %) followed by ribs (52.0 %) and femur (30.0 %). Spread of bony metastases among the bony skeleton has distribution manner not only to the right or to the left. Metastatic bony lesions of prostate cancer are located mainly in spine (58.0%) followed by ribs (52.0 %) and femur (30.0 %). Patients with extensive bone metastasis had significantly higher frequency of skull, spine, scapula, humerous, sternum, ribs, iliac bone, ischium, and femur metastases

DOI 10.11648/j.ijmi.20150306.15
Published in International Journal of Medical Imaging (Volume 3, Issue 6, November 2015)
Page(s) 137-142
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Prostate Cancer, Bone Scan, Bone Metastases, MDP

References
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013; 63(1): 11–30.
[2] Scosyrev E, Messing EM, Mohile S, et al. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012; 118(12): 3062–3070.
[3] Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106(7): 1624–1633.
[4] Russel P.J, P.Jackson,E.A. Kingsley. Prostate cancer methods and protocols. Methods in Molecular Medicine.2003; 81: 1-19.
[5] Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ.2010; 341: c4543.
[6] Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide. IARC Cancer Base No. 10.Int Agency Res Canc 2010.
[7] Freddy S, Max P, Zvavahera C, et al. Cancers. In Disease and Mortality in Sub-Saharan Africa. World Bank; 2006.
[8] Danley KL, Richardson JL, Bernstein L, et al. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States).Cancer Causes Control 1995; 6(6): 492-498.
[9] Vinjamoori AH, Jagannathan JP, Shinagare AB, et al. A typical metastases from prostate cancer: 10-year experience at a single institution. Am J Roentgenol 2012; 199(2): 367-372.
[10] Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer.Eur Urol 2006; 49(3): 429-440.
[11] Rajendiran G, Green L, Chhabra G. A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. Int J Case Rep Image 2011; 2(9): 16-20.
[12] Migita T, Maeda K, Ogata N. A case of prostate cancer associated with osteolytic bone metastases.Hinyokika Kiyo 1999; 45(5): 371-374.
[13] Lin K, Szabo Z, Chin BB, Civelek AC. The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med. 1999; 24: 579–582.
[14] Conti G, La Torre G, Cicalese V, et al. Prostate cancer metastases to bone: Observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the metauro protocol and of patient baseline features. Arch Ital Urol Androl. 2008; 80: 59–64.
[15] Maffioli L, Florimonte L, Pagani L, et al. Current role of bone scan with phosphonates in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004; 31(Suppl 1): S143–S148.
[16] Wang CY, Wu GY, Shen MJ, et al. Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol Lett. 2013 Jan; 5(1): 391-397.
[17] Scher B, Seitz M, Albinger W, et al. Value of PET and PET/CT in the diagnostics of prostate and penile cancer. Recent Results Cancer Res. 2008; 170: 159-79.
[18] Levren G, Sadik M, Gjertsson P, et al. Relation between pain and skeletal metastasis in patients with prostate or breast cancer. Clin Physiol Funct Imaging. 2011 May; 31(3): 193-5.
[19] Helyar V, Mohan HK, Barwick T, et al: The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010; 37: 706–713.
[20] Elabbady A, Eid A, Fahmy A, et al. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol. 2014; 67(4): 351-6.
[21] Pal RP, Thiruudaian T, Khan MA. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Asian J Androl. 2008 Nov; 10(6): 890-5.
[22] Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014 Feb; 74(2): 210-6.
[23] Kakhki VR, Anvari K, Sadeghi R, et al. Pattern and distribution of bone metastases in common malignant tumors. Nucl Med Rev Cent East Eur. 2013; 16(2): 66-9.
Author Information
  • Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt

  • Nuclear Medicine & Clinical Oncology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt

  • Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt

  • Radiology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Cite This Article
  • APA Style

    Ashraf Anas Zytoon, Eman Abdel Razek Tawfek, Adel Mohamed Elwakil, Gilan Ibrahim Aladle. (2015). Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer. International Journal of Medical Imaging, 3(6), 137-142. https://doi.org/10.11648/j.ijmi.20150306.15

    Copy | Download

    ACS Style

    Ashraf Anas Zytoon; Eman Abdel Razek Tawfek; Adel Mohamed Elwakil; Gilan Ibrahim Aladle. Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer. Int. J. Med. Imaging 2015, 3(6), 137-142. doi: 10.11648/j.ijmi.20150306.15

    Copy | Download

    AMA Style

    Ashraf Anas Zytoon, Eman Abdel Razek Tawfek, Adel Mohamed Elwakil, Gilan Ibrahim Aladle. Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer. Int J Med Imaging. 2015;3(6):137-142. doi: 10.11648/j.ijmi.20150306.15

    Copy | Download

  • @article{10.11648/j.ijmi.20150306.15,
      author = {Ashraf Anas Zytoon and Eman Abdel Razek Tawfek and Adel Mohamed Elwakil and Gilan Ibrahim Aladle},
      title = {Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer},
      journal = {International Journal of Medical Imaging},
      volume = {3},
      number = {6},
      pages = {137-142},
      doi = {10.11648/j.ijmi.20150306.15},
      url = {https://doi.org/10.11648/j.ijmi.20150306.15},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.ijmi.20150306.15},
      abstract = {Prostate cancer (PCa) represents the most common non-cutaneous malignancy for men, where an estimated 241,740 new cases will be diagnosed in 2013 in the United States [1]. Whereas most of those new diagnoses will be clinically localized, up to 17% of patients may experience metastatic disease, in which the risk of cancer- specific mortality is increased [2]. In this context, it is well established that, beyond regional lymph nodes, the skeleton represents the most common metastatic site [3].The study aims to evaluate the pattern of distribution of bone metastases in prostate cancer patients by 99mTc- methylene diphosphonate (99mTc-MDP) bone scintigraphy. It was formed in 150 patients with pathologically proven prostate cancer and presented for bone scans with 99mTc-methylene diphosphonate (99mTc-MDP) for detection and evaluation of bone metastases. It was noted that patients with bone metastases had significantly higher frequency of bone pain when compared with patients without and noted that spine was the most commonly affected site (60.0 %) followed by ribs (52.0 %) and femur (30.0 %). Spread of bony metastases among the bony skeleton has distribution manner not only to the right or to the left. Metastatic bony lesions of prostate cancer are located mainly in spine (58.0%) followed by ribs (52.0 %) and femur (30.0 %). Patients with extensive bone metastasis had significantly higher frequency of skull, spine, scapula, humerous, sternum, ribs, iliac bone, ischium, and femur metastases},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Evaluation of Distribution Features of Bone Metastases by Bone Scintigraphy in Prostate Cancer
    AU  - Ashraf Anas Zytoon
    AU  - Eman Abdel Razek Tawfek
    AU  - Adel Mohamed Elwakil
    AU  - Gilan Ibrahim Aladle
    Y1  - 2015/11/26
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ijmi.20150306.15
    DO  - 10.11648/j.ijmi.20150306.15
    T2  - International Journal of Medical Imaging
    JF  - International Journal of Medical Imaging
    JO  - International Journal of Medical Imaging
    SP  - 137
    EP  - 142
    PB  - Science Publishing Group
    SN  - 2330-832X
    UR  - https://doi.org/10.11648/j.ijmi.20150306.15
    AB  - Prostate cancer (PCa) represents the most common non-cutaneous malignancy for men, where an estimated 241,740 new cases will be diagnosed in 2013 in the United States [1]. Whereas most of those new diagnoses will be clinically localized, up to 17% of patients may experience metastatic disease, in which the risk of cancer- specific mortality is increased [2]. In this context, it is well established that, beyond regional lymph nodes, the skeleton represents the most common metastatic site [3].The study aims to evaluate the pattern of distribution of bone metastases in prostate cancer patients by 99mTc- methylene diphosphonate (99mTc-MDP) bone scintigraphy. It was formed in 150 patients with pathologically proven prostate cancer and presented for bone scans with 99mTc-methylene diphosphonate (99mTc-MDP) for detection and evaluation of bone metastases. It was noted that patients with bone metastases had significantly higher frequency of bone pain when compared with patients without and noted that spine was the most commonly affected site (60.0 %) followed by ribs (52.0 %) and femur (30.0 %). Spread of bony metastases among the bony skeleton has distribution manner not only to the right or to the left. Metastatic bony lesions of prostate cancer are located mainly in spine (58.0%) followed by ribs (52.0 %) and femur (30.0 %). Patients with extensive bone metastasis had significantly higher frequency of skull, spine, scapula, humerous, sternum, ribs, iliac bone, ischium, and femur metastases
    VL  - 3
    IS  - 6
    ER  - 

    Copy | Download

  • Sections